Roper Technologies blackout on executive trading
Roper Technologies has implemented a trading blackout for executives and directors, required for the transition of its 401(k) plans to a new recordkeeper, Fidelity Investments.
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Roper Technologies has implemented a trading blackout for executives and directors, required for the transition of its 401(k) plans to a new recordkeeper, Fidelity Investments.
Fidelity Ethereum Fund filed its Third Amended and Restated Trust Agreement with the SEC on August 7, which outlines the governance, trustee duties, and funding procedures for the …
HyOrc Corp appointed Focal Accounting CPA LLC as its replacement auditor. This follows a history of failing to meet filing deadlines and is immediate news to address ongoing regula…
Chase Issuance Trust filed an 8-K on August 10, 2026, disclosing portfolio information regarding owned credit card receivables and accounts.
Faraday Future Telecom Technology (hun) received notice that it has regained compliance with Nasdaq's minimum bid price requirement. The company also announced technological breakt…
Sphere 3D, Inc. (PLAB) plans to adopt a shareholder rights plan agreement to protect shareholders during potential takeover bids. The filing details the agreement with TSX Trust Co…
Silence Therapeutics announced that divesiran met its primary efficacy endpoint in a Phase 2 trial for polycythemia vera, with high response rates and no new safety findings. This …
Phase 2 trial of ABCL635 met primary endpoints for hot flash reduction. The results mark a new efficacy benchmark for the treatment of vasomotor symptoms.
Tenax Therapeutics reports that its Phase 3 LEVEL study for TNX-103 did not meet its primary endpoint, though exploratory analysis showed reduced NT-proBNP and improved walk distan…
MoonLake Immunotherapeutics reported positive results from its Phase 3 IZAR-1 trial for sonelokimab in psoriatic arthritis, alongside cash runway projections to mid-2028, reflectin…
Aquestive Therapeutics announced positive human factors and pharmacokinetic study results for its Anaphylm (dibutepinephrine) sublingual film, supporting its planned NDA resubmissi…
Silexion Therapeutics Corp filed an exhibit marked as a slide deck in the SEC filing. It includes a standard forward-looking statement risk section indicating the company is a deve…
NexMetals Mining announced the filing of an NI 43-101 technical report for its Selkirk Project in Botswana, which outlines a significant increase in copper equivalent metal invento…
ServisFirst Bancshares, Inc. cautions investors that financial guidance and future operational projections are subject to various risks including market conditions, regulatory chan…
MGP Ingredients Inc. amended its credit agreement to modify definitions in the revolving credit facility, effective August 6, 2026. Wells Fargo acts as administrative agent for the…
Stewards, Inc. amended and restated its bylaws on August 6, 2026, detailing meeting procedures for shareholders, including annual meetings on April 12 and the use of remote communi…
NusaTrip has been notified by Nasdaq that its securities will be delisted due to previous failures to file required periodic reports and significant control risks stemming from the…
The auditor has consented to the Griffon Corp 2025 annual report, with separate financial statements issued pending retrospective adjustments. Positive sentiment.
AbCellera Biologics will release Phase 2 trial data for ABCL635 on Monday, August 10, 2026. This potential first-in-class antibody for menopause symptoms is expected to drive inves…
Agassi Sports Entertainment Corp. ratified and validated various historical corporate acts, primarily stock issuances and board appointments, due to lost documentation. The filing …